Cyclosporine in the treatment of cutaneous T cell lymphoma.
We present our observations on the use of cyclosporine in the treatment of three patients with mycosis fungoides and two patients with Sézary syndrome. The patients with mycosis fungoides showed mild improvement of short duration. One patient with Sézary syndrome had significant improvement during 2 years of treatment. It is unlikely that cyclosporine alone will be sufficient therapy for cutaneous T cell lymphoma. However, lower doses in conjunction with other immunomodulators may minimize potential side effects and lead to longer lasting clinical improvement.
Street
M L
ML
Department of Dermatology, Mayo Clinic, Rochester, MN 55905.
Muller
S A
SA
Pittelkow
M R
MR
D000368:Aged; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D003524:Cyclosporins